Published on 27/12/2025
Regulatory Timelines and Review Models in Turkey
In the context of increasing globalization of pharmaceutical markets, understanding the regulatory frameworks of emerging markets such as Turkey is crucial for stakeholders in the pharmaceutical industry. This article serves as a detailed step-by-step tutorial for regulatory affairs professionals seeking insights into Turkey’s regulatory timelines and review models, facilitating strategic decision-making for effective drug development and market access.
Understanding the Regulatory Framework in Turkey
Turkey, recognized for its strategic position bridging Europe and Asia, presents significant opportunities for pharmaceutical companies. The regulatory authority governing pharmaceutical and medical device sectors in Turkey is the Turkey Medicines and Medical Devices Authority (TMMDA). The TMMDA oversees the approval process for new drug applications, ensuring adherence to international standards and national health regulations.
As part of the regulatory landscape, Turkey aligns with several international standards while also maintaining specific national requirements. Understanding this dual framework is essential for seamless navigation of market entry and compliance obligations. The TMMDA operates under various laws, notably the Pharmaceuticals and Medical Devices Law, which governs the registration and approval processes for medicines and medical devices within the country.
Key Regulatory Timelines in Turkey
Understanding regulatory timelines is critical for planning and execution of market strategies. The approval process for pharmaceuticals via the TMMDA typically follows these key stages:
1. Pre-Submission Meeting
Before initiating a formal submission, companies are encouraged to hold a pre-submission meeting with TMMDA. This meeting allows for the clarification of regulatory expectations and guidelines prior to the submission of the market authorization application (MAA). It typically takes 2–4 weeks to arrange, depending on scheduling.
2. Submission of the Market Authorization Application (MAA)
Once ready, companies can submit their MAA. The TMMDA has specified a 365-day review timeline for most applications. However, this period can extend if additional information or clarification is requested. Applications are assessed for completeness and compliance with regulatory standards before they move into detail evaluation stages.
3. Review Process
The review process within TMMDA can be broken down as follows:
- Administrative Review: The initial assessment, focusing on application completeness and adherence to submission guidelines.
- Scientific Review: A comprehensive evaluation of the clinical data, preclinical data, and risk benefit assessment.
- Evaluation of Benefit-Risk Profile: Based on the available evidence, an assessment of the therapeutic benefits against potential risks is conducted.
This entire evaluation phase generally takes around 6–8 months but may be expedited based on the therapeutic area and public health needs.
4. Post-Approval Evaluation
Once the drug is approved, ongoing pharmacovigilance and further clinical data collection are required as part of the life cycle management of the product. The TMMDA mandates that companies submit periodic safety update reports (PSURs) and other relevant documentation to ensure patient safety continues to be upheld post-approval.
Review Models and Fast-Track Opportunities
The TMMDA has established various review models to facilitate timely access to essential medicines.
1. Priority Review
Medicines that address serious conditions or that offer significant improvements over existing treatments may qualify for priority review, significantly shortening the total review timeline. In this case, TMMDA seeks to expedite the process wherever possible, allowing expedited access for patients in need.
2. Conditional Approval
Conditional approval may be granted based on preliminary clinical data, especially for products addressing critical unmet medical needs. This pathway allows for earlier market access, with the stipulation that further clinical data will be generated and submitted thereafter to confirm the product’s ongoing safety and efficacy.
3. Fast-Track Designation
Specific products, especially those involved in the treatment of public health emergencies such as communicable diseases, may be eligible for fast-track designation. This model allows for a more efficient review process, facilitating quicker access to market while adhering to stipulated requirements for data submission.
Strategic Considerations for Global Regulatory Strategy
When planning for regulatory submissions in Turkey, it is essential to develop a comprehensive global regulatory strategy that encompasses FDA, EMA, and MHRA alignment methodologies. Companies operating in emerging markets must be cognizant of the variances in the regulatory landscapes between these agencies and the TMMDA.
1. Ensure Compliance with Local and International Standards
Regulatory professionals should ensure that all submissions comply with both local Turkish regulations and international standards as per guidelines set by ICH-GCP and other relevant authorities. This dual compliance is crucial to avoid delays or complications.
2. Continuous Monitoring of Regulatory Changes
The regulatory landscape in Turkey is subject to change, influenced by evolving health policies and emerging global health needs. Therefore, it is imperative for companies to stay informed of any changes or updates in TMMDA regulations to ensure ongoing compliance and to preemptively address possible challenges during the submission process.
3. Engage Local Regulatory Expertise
Partnering with experienced local regulatory consulting services in Turkey can enhance the efficacy of your submissions. A thorough understanding of local nuances can facilitate smoother interactions with regulatory authorities and assist in navigating challenges specific to the Turkish market.